Table 1.

Matrix of features observed in 6 case studies

Features	Tomosynthesis	Pembrolizumab	Lumacaftor / ivacaftor	Nivolumab	Rifaximine	Eculizumab
Features of case study
Drug		X	X	X	X	X
Other technology	X
ICER above threshold	X	X	X	X
Single arm studies		X
Indirect treatment comparison		X
Long-term extrapolation beyond available data		X	X	X	X	X
Clinical evidence from setting different to decision problem	X	X	X	X	X	X
Issues in clinical evidence due to intermediate outcomes			X
Issues in TRUST model aspects observed in case study
Issues with context / scope	X	X				X
Issues with structural uncertainty		X			X
Issues with selection of evidence / review		X	X		X	X
Issues with effectiveness			X	X	X
Issues with relative effectiveness	X		X	X	X
Issues with adverse events		X			X	X
Issues with HRQoL	X	X	X		X	X
Issues with cost & resource use	X	X	X	X		X
Issues with model implementation	X				X	X